CDK9 is overexpressed in various solid and hematological malignancies, where CDK9 is the principal regulator that stimulates transcriptional elongation, through which short-lived antiapoptotic proteins (e.g., Mcl-1) are overexpressed, leading to cancer cells becoming resistant to apoptosis [9]. This evidence concerns the gene CDK9 and cancer.